2 edition of Oestrogen, antioestrogen and cytotoxic drug interactions in human breast cancer cells. found in the catalog.
Oestrogen, antioestrogen and cytotoxic drug interactions in human breast cancer cells.
Written in English
Thesis (Ph. D.)--The Queen"s University of Belfast, 1986.
|The Physical Object|
The issue of acquired resistance to breast cancer regimes such as tamoxifen continues to negatively affect clinical outcomes. While many mechanisms of resistance have been discovered [1, 2], there is evidence now of acquired resistance through adaptation of the oestrogen receptor itself leading to tumour progression .A thorough understanding of the processes involved in the receptor's Author: Chrisen Ramkaran, Alacoque Browne, Leonie Young. A case in point is the use of oestrogen receptor status in making decisions about endocrine therapy. Oestrogen receptors are required for oestrogen stimulated growth and proliferation of breast cancer. They are found to some degree in % of breast tumours. Endocrine treatments are designed to antagonise the effects of by:
Resistance-causing pathways may already be active in a subpopulation of cancer cells within a tumour that contain the active drug target (ADT) prior to treatment (Figure 1, A.b), or activated in ADT-positive cancer cells upon treatment (Figure 1, A.c). They can alternatively be active in cancer cells that do not contain ADT (Figure 1, B.a & B.b).Author: David J. Britton, Pedro R. Cutillas. Breast cancer is the second leading cause of cancer deaths among American women. At the time of diagnosis about 2/3 of human breast cancers are ER positive. Estrogens stimulate the proliferation and metastatic potential of these early stage breast cancers.
Chemotherapy is also hindered by intrinsic or acquired resistance of breast cancer cells. Because more than 50% of human breast cancers express receptors for LHRH, a targeted chemotherapy with cytotoxic LHRH analogs AN or AN may help overcome these drawbacks [1, 3–5, 7, 9, 13, 14].Cited by: In established breast cancer, removal or reduction of estrogen often results in shrinkage of breast cancer or in prevention of recurrence. Thus, both physicians and patients remain extremely cautious about the routine clinical use of estrogen or progesterone in women who have ever had a .
Guide to archives and other collections of documents relating to Surrey
Eliminating mandatory retirement
The Trinity factor
Tachai, standard bearer in Chinas agriculture.
Sheep breeding and management.
Buddhist conquest of China
Legislative Assembly and Legislative Council draft electoral roll ... 30th June, 1973.
Southern Pacific Across the Southwest
collected essays of Leslie Fiedler.
Family centered case management with sexually aggressive youth
Hannegan C. Norvell.
symposium on the chemical basis of heredity
Manuscript notes on weaving for second and third year..
Memorial services held in the House of representatives of the United States, together with remarks presented in eulogy of Florian Lampert, late a representative from Wisconsin.
Spelling made easy
process of program evaluation: a guide for managers.
Starting and managing a retail flower shop
Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology.
; (10)– doi: /enCited by: Hormone therapy works by lowering the amount of oestrogen in the body, or by blocking its ability to attach to breast cancer cells.
It may be used to stop oestrogen production in the ovaries (before menopause), prevent the production of oestrogen in fat cells (post-menopause), or prevent oestrogen from interacting with tumour cells. Oestrogen agonist activity was assessed for a range of concentrations for each phytoestrogen using a variety of validated assays based in MCF-7 human breast cancer cells (Byford et al.Matsumura et al.
): 1) ligand ability to bind to ER from MCF-7 cell lysates in a competitive binding assay, 2) ligand ability to regulate expression of Cited by: Cancer Res. 46 () 2. Westley B. and May F. B.: Oestrogen regulates cathepsin D antioestrogen and cytotoxic drug interactions in human breast cancer cells.
book levels in oestrogen responsive human breast cancer cells. Nucl. Acids Res. 15 () 3. May F. and Westley B. R.: Identification and characterisation of oestrogen regulated RNAs in human breast cancer by: The use of partially purified preparations of the human uterine oestrogen receptor has enabled, for the first time, a study of the binding of the steroidal, pure antioestrogen ICI[N-n-butyl(3, 17β-dihydroxy-oestra-1,3,5 (10)-trien-7α-yl)N-methyl-undecamide] to the oestrogen by: Darbre, P.
() Molecular mechanisms of oestrogen action on growth of human breast cancer cells in culture. Hormone Molecular Biology and Clinical Investigation, 9 (1). ISSN Full text not archived in this repository.
Purpose: There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrogen target reproductive by: Lippman ME and Bolan G () Oestrogen-responsive human breast cancer in long term tissue culture Nature () –3 DOI: /a0 PMID: Tamoxifen has been the endocrine treatment of choice for all stages of oestrogen receptor positive breast cancer for 20 years and the first chemical therapeutic to be tested to reduce the.
The oestrogen receptor (ER) has proven to be an extraordinarily successful target for breast cancer treatment and prevention. The clinical use of tamoxifen, a nonsteroidal antioestrogen, demonstrated (1) that the strategic use of adjuvant tamoxifen in ER-positive patients could save lives and (2) that a selective ER modulator (SERM) could reduce the incidence of breast cancer in high-risk by: Breast cancer represents the leading cause of cancer death among women in developed countries .Among the various prognostic factors, lack of oestrogen receptor (ER) has consistently been associated with poorer prognosis .Most human breast cancers express ER-α, and the presence of this receptor is generally considered an indication of hormone dependence .Cited by: Tamoxifen still remains the most frequently used antioestrogen for the treatment of breast cancer.
However, its efficacy is often limited by the emergence of acquired resistance and it has been suggested that, in some instances, this may involve oestrogen receptor (ER) : Abdelwahab Bensmail, Iain Robert Hutcheson, M. Giles, Julia Margaret Wendy Gee, Robert Ian Nicholson.
Inducible upregulation of oestrogen receptor- 1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells L C Murphy1,2, B Peng1,2, A Lewis1,2, J R Davie1,2, E Leygue1,2, A Kemp2, K Ung2, M Vendetti3 and R Shiu2,3 1Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada 2Manitoba Institute of Cell Biology, University of.
Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response to chemotherapy.
However, ER+ tumours seem to grow more slowly than ER Cited by: The primary culture of human breast carcinoma cells was obtained originally by pleural effusion from a female patient with metastatic disease. A stable epithelioid cell line, MCF-7, was derived from free-floating passages and had been maintained through 71 weekly subcultivations.
The cells were cultured in. oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy.
This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4.
estrogen receptor: [ re-sep´tor ] 1. a molecule on the cell surface (cell-surface or membrane receptor) or within a cell, usually in its nucleus (nuclear receptor) that recognizes and binds with specific molecules, producing some effect in the cell; e.g., the cell-surface receptors of immunocompetent cells that recognize antigens, complement.
Oestrogen-suppressing drugs substantially reduce breast cancer deaths A class of hormonal drugs called aromatase inhibitors substantially reduce the risk of death in postmenopausal women with the most common type of breast cancer, a major study of more t women shows.
Most breast tumours express the oestrogen receptor-α (ER), and this transcription factor is seen as an important drug target for the treatment of breast cancer. breast cancer, a comprehensive evaluation system, which includes tumor-stromal interactions, should be considered.
In this study, we developed a novel system to detect the overall estrogen signals based on tumor-stromal interactions by visualization. Materials and Methods Cells and cell culture.
The human breast cancer cell line MCF-7 was. ously in breast cancer . Recent reports also demon-strate involvement of oestrogen signalling in the carcinogenesis of non-classical oestrogen-sensitive tis-sues including colon, prostate, lung, skin, and brain [19– 23]. The complex biological effects of oestrogens are mediated by two distinct receptor subtypes - ERα and.Purpose Our publications demonstrate that physiological concentrations of oestrogen (E 2) induce endoplasmic reticulum and oxidative stress which finally result in apoptosis in E 2-deprived breast cancer cells, MCFC.
c-Src is involved in the process of E 2-induced mimic the clinical administration of c-Src inhibitors, we treated cells with either E 2, a c-Src inhibitor PP2, or Cited by: Yes.
Most breast cancers are ER positive, and clinical trials have tested whether hormone therapy can be used to prevent breast cancer in women who are at increased risk of developing the disease.
A large NCI-sponsored randomized clinical trial called the Breast Cancer Prevention Trial found that tamoxifen, taken for 5 years, reduced the risk of developing invasive breast cancer by about 50%.